SCHEMBL1198337

SCHEMBL1198337

COc1ccc(CNc2ncccc2CNC2CCN(C(=O)O)CC2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.46
CYP1A2 P05177 5/20 0.45
CYP3A4 P08684 5/20 0.45
CYP2D6 P10635 5/20 0.45
CYP2C19 P33261 4/20 0.45
CLK4 Q9HAZ1 3/20 0.45
CYP2C9 P11712 3/20 0.45
MAPT P10636 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPK1 P28482 2/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 4/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2101049 0.89 EPHX2 (0.49) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL2100254 0.87 CYP1A2 (0.41) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL1198634 0.87 KDM4C (0.49) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4733035 0.87 KMT2A (0.54) MEN1KMT2ASMN1; SMN2KDM4EPOLB
SCHEMBL6467853 0.79 PKM (0.40) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL6467856 0.79 PKM (0.40) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL3267374 0.76 EPHX2 (0.49) KDM4CMAPTMEN1KMT2AALDH1A1
SCHEMBL12873829 0.75 MEN1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL27003454 0.75 KMT2A (0.57) MEN1KMT2ASMN1; SMN2KDM4EMAPK1
SCHEMBL21274582 0.75 KDM4C (0.45) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2039694-B1 CGRP receptor antagonists MERCK SHARP & DOHME (US) 2014-03-26 EP disclosed
US-7893052-B2 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2011-02-22 US disclosed
US-20100298303-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-11-25 US disclosed
US-7772224-B2 Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches MERCK SHARP & DOHME CORP. (US) 2010-08-10 US disclosed
US-7745427-B2 CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2010-06-29 US disclosed
US-20090192139-A1 Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches MERCK SHARP & DOHME LLC 2009-07-30 US disclosed
US-7534784-B2 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide MERCK + CO., INC. (US) 2009-05-19 US disclosed
EP-2039694-A1 CGRP receptor antagonists Merck & Co., Inc. (US) 2009-03-25 EP disclosed
US-7452903-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2008-11-18 US disclosed
US-20080280857-A1 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2008-11-13 US disclosed
US-20080090806-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-04-17 US disclosed
US-20070225272-A1 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-09-27 US disclosed
US-7235545-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2007-06-26 US disclosed
US-6953790-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2005-10-11 US disclosed
US-20040229861-A1 CGRP receptor antagonists MERCK SHARP & DOHME LLC 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090806-A1 Cgrp Receptor Antagonists CCKBR, BDKRB1, BDKRB2 KDM4C 3502/4885CYP1A2 2161/4885CYP3A4 3155/4885
US-20040229861-A1 CGRP receptor antagonists CCKBR, CCKAR, CALCRL KDM4C 3908/4885CYP1A2 1950/4885CYP3A4 3378/4885
US-20090192139-A1 Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches CALCRL, CALCB, CALCR KDM4C 1955/4885CYP1A2 1871/4885CYP3A4 2594/4885
US-20100298303-A1 CGRP RECEPTOR ANTAGONISTS CCKBR, BDKRB1, BDKRB2 KDM4C 3619/4885CYP1A2 1991/4885CYP3A4 3228/4885
US-20070225272-A1 CGRP receptor antagonists CCKBR, BDKRB1, BDKRB2 KDM4C 3619/4885CYP1A2 1991/4885CYP3A4 3228/4885
US-20080280857-A1 CGRP receptor antagonists CCKBR, BDKRB1, BDKRB2 KDM4C 3619/4885CYP1A2 1991/4885CYP3A4 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.